Practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care. Del Rivero, J., Mailman, J., Rabow, M. W., Chan, J. A., Creed, S., Kennecke, H. F., Pasieka, J., Zuar, J., Singh, S., and Fishbein, L. (2023). Endocrine-Related Cancer 30, 7, e220226, https://doi.org/10.1530/ERC-22-0226
A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-Resistant Tumors.Chamberlain CE, German MS, Yang K, Wang J, VanBrocklin H, Regan M, Shokat KM, Ducker GS, Kim GE, Hann B, Donner DB, Warren RS, Venook AP, Bergsland EK, Lee D, Wang Y, Nakakura EK. Mol Cancer Ther. 2018 Sep 25. pii: molcanther.1204.2017. doi: 10.1158/1535-7163.MCT-17-1204. [Epub ahead of print]
PMID: 30254185
Identification of high-risk human papillomavirus and Rb/E2F pathway genomic alterations in mutually exclusive subsets of colorectal neuroendocrine carcinoma.
Shamir ER, Devine WP, Pekmezci M, Umetsu SE, Krings G, Federman S, Cho SJ, Saunders TA, Jen KY, Bergsland E, Jones K, Kim GE, Kakar S, Chiu CY, Joseph NM. Mod Pathol. 2018 Sep 20. doi: 10.1038/s41379-018-0131-6. [Epub ahead of print]
Mulvey CK, Bergsland EK. J Oncol Pract. 2018 Aug;14(8):487-489. doi: 10.1200/JOP.18.00440. No abstract available. PMID: 30096272
Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors. Singh S, Moody L, Chan DL, Metz DC, Strosberg J, Asmis T, Bailey DL, Bergsland E, Brendtro K, Carroll R, Cleary S, Kim M, Kong G, Law C, Lawrence B, McEwan A, McGregor C, Michael M, Pasieka J, Pavlakis N, Pommier R, Soulen M, Wyld D, Segelov E; Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) Follow-up Working Group.
JAMA Oncol. 2018 Jul 26. doi: 10.1001/jamaoncol.2018.2428. [Epub ahead of print] . PMID: 30054622
NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.
Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB 3rd, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW 2nd, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G. J Natl Compr Canc Netw. 2018 Jun;16(6):693-702. doi: 10.6004/jnccn.2018.0056. PMID: 29891520
Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome.
Weickert MO, Kaltsas G, Hörsch D, Lapuerta P, Pavel M, Valle JW, Caplin ME, Bergsland E, Kunz PL, Anthony LB, Grande E, Öberg K, Welin S, Lombard-Bohas C, Ramage JK, Kittur A, Yang QM, Kulke MH. Clin Ther. 2018 Jun;40(6):952-962.e2. doi: 10.1016/j.clinthera.2018.04.006. Epub 2018 May 1. PMID: 29724499
Anthony L, Ervin C, Lapuerta P, Kulke MH, Kunz P, Bergsland E, Hörsch D, Metz DC, Pasieka J, Pavlakis N, Pavel M, Caplin M, Öberg K, Ramage J, Evans E, Yang QM, Jackson S, Arnold K, Law L, DiBenedetti DB. Clin Ther. 2017 Nov;39(11):2158-2168. doi: 10.1016/j.clinthera.2017.09.013. Epub 2017 Oct 23. PMID: 29074312
Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. Hope TA, Bergsland EK, Bozkurt MF, Graham M, Heaney AP, Herrmann K, Howe JR, Kulke MH, Kunz PL, Mailman J, May L, Metz DC, Millo C, O'Dorisio S, Reidy-Lagunes DL, Soulen MC, Strosberg JR. J Nucl Med. 2018 Jan;59(1):66-74. doi: 10.2967/jnumed.117.202275. Epub 2017 Oct 12. No abstract available. PMID: 29025982
The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society. Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, Law CH, Liu EH, Kim MK, Menda Y, Morse BG, Bergsland EK, Strosberg JR, Nakakura EK, Pommier RF. Pancreas. 2017 Jul;46(6):715-731. doi: 10.1097/MPA.0000000000000846. Review. PMID: 28609357
Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, Kunz PL, O'Dorisio TM, Salem R, Segelov E, Howe JR, Pommier RF, Brendtro K, Bashir MA, Singh S, Soulen MC, Tang L, Zacks JS, Yao JC, Bergsland EK.
Pancreas. 2017 Jul;46(6):707-714. doi: 10.1097/MPA.0000000000000850. Review.
PMID: 28609356
Wang VE, Young L, Ali S, Miller VA, Urisman A, Wolfe J, Bivona TG, Damato B, Fogh S, Bergsland EK. Oncologist. 2017 Jul;22(7):768-773. doi: 10.1634/theoncologist.2017-0054. Epub 2017 May 15. PMID: 28507205
Herring M, Huynh L, Duh MS, Vekeman F, Tiew A, Neary M, Bergsland E. Med Oncol. 2017 May;34(5):88. doi: 10.1007/s12032-017-0927-0. Epub 2017 Apr 9. PMID: 28393314
Lower gastrointestinal neuroendocrine neoplasms associated with hereditary cancer syndromes: a case series. Kidambi TD, Pedley C, Blanco A, Bergsland EK, Terdiman JP. Fam Cancer. 2017 Oct;16(4):537-543. doi: 10.1007/s10689-017-9979-8 PMID: 28283864
Complicated Case Presentation: Management of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1. Mulvey CK, Van Loon K, Bergsland EK, Masharani U, Nakakura EK. Pancreas. 2017 Mar;46(3):416-426. doi: 10.1097/MPA.0000000000000770. Review. PMID: 28187108
Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. Kulke MH, Hörsch D, Caplin ME, Anthony LB, Bergsland E, Öberg K, Welin S, Warner RR, Lombard-Bohas C, Kunz PL, Grande E, Valle JW, Fleming D, Lapuerta P, Banks P, Jackson S, Zambrowicz B, Sands AT, Pavel M. J Clin Oncol. 2017 Jan;35(1):14-23. Epub 2016 Oct 28. PMID: 27918724
Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials. Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland EK. Pancreas. 2016 Nov;45(10):1394-1400. PMID: 27171514
(415) 476-2212